Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a retrospective/prospective observational multicentric trial on patients with bone metastases from NENs.
General objectives:
Background, rationale and objectives:
On March 25th 2015 the Ethical Committee from IEO approved the academic study entitled "Bone metastases in neuroendocrine tumors (NETs): a survey on natural history, prognostic value and treatment approach", version 1.0 30-Jan-2015. This was a retrospective study led to report how the issue bone metastases from NETs was handle in real practice. Preliminary data related to 321 patients from 18 Italian centers were presented as a poster at the ESMO 2017 congress (Fazio et al. 448P) and they will be included in a manuscript to submit for publication in a peer-review journal. The current protocol regards the continuation of the retrospective analysis, starting since 2014, since the previous study required data collection up to 2013, and at the same time a multicenter prospective observational analysis on the topic.
Duration of the study The study will regard patients fulfilling the eligibility criteria from 2014 to 2021. Data analysis will be completed by the year 2021.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Overall survival (OS) will be calculated from the date of BM diagnosis to the date of death | 01/2021 - 12/2021 |
| Influence of skeletal related events (SRE) on survival | Influence of skeletal related events (SRE) on overall survival (OS) | 01/2021 - 12/2021 |
| Correlation between SRE and time from bone metastasis and SRE, site of one metastases, number of bone metastases, morphology of bone metastases, LDH | To evaluate the correlation between SRE and time from bone metastasis and SRE, site of one metastases, number of bone metastases, morphology of bone metastases, LDH | 01/2021 - 12/2021 |
| Influence of the use of bisphosphonates or RANK-ligands | To evaluate the influence of the use of bisphosphonates or RANK-ligands on overall survival | 01/2021 - 12/2021 |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation from bone metastases and age, gender, primary site, Ki-67, grade of differentiation | To evaluate the correlation between bone metastases and patients and tumor's features | 01/2021 - 12/2021 |
| Natural history (time between diagnosis of NEN and first diagnosis of bone metastasis, frequency and time to SRE, sites of bone metastases) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with bone metastases from NENs histologically proved.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Darina Tamayo, PharmSc. | Contact | +39(0)294372686 | darina.tamayo@ieo.it | |
| Cristina Mazzon, Ph.D. | Contact | +39(0)294372686 |
| Name | Affiliation | Role |
|---|---|---|
| Nicola Fazio, M.D., Ph.D. | European Institute of Oncology, IEO, IRCCS | Study Chair |
| Francesca Spada, M.D., Ph.D. | European Institute of Oncology, IEO, IRCCS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| European Institute of Oncology, IEO, IRCCS | Recruiting | Milan | 20141 | Italy |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29295881 | Result | Harding JJ, Abu-Zeinah G, Chou JF, Owen DH, Ly M, Lowery MA, Capanu M, Do R, Kemeny NE, O'Reilly EM, Saltz LB, Abou-Alfa GK. Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024. | |
| 30893350 | Result |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D018278 | Carcinoma, Neuroendocrine |
| ID | Term |
|---|---|
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
To describe the natural history time between diagnosis of NEN and first diagnosis of bone metastasis, frequency and time to SRE, sites of bone metastases |
| 01/2021 - 12/2021 |
| Radiological diagnosis (CT, MRI) | To describe the morphological features of bone metastases in patients with NEN | 01/2021 - 12/2021 |
| Functional diagnosis (68GaPET/CT-DOTA-peptide, 18FDGPET/CT) | To To describe the functional features of bone metastases in patients with NEN | 01/2021 - 12/2021 |
| Impact of antitumor therapy on bone metastases behavior | To describe the global impact of antitumor therapies on bone metastases behavior | 01/2021 - 12/2021 |
| Impact of supportive care | To describe the global impact of supportive care on overal survival | 01/2021 - 12/2021 |
| Grisanti S, Bianchi S, Locati LD, Triggiani L, Vecchio S, Bonetta A, Bergamini C, Conte P, Airoldi M, Merlano M, Carlini P, Ibrahim T, Rossetto C, Alfieri S, Pronzato P, Tonoli S, Maroldi R, Nicolai P, Resteghini C, Magrini SM, Berruti A. Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. PLoS One. 2019 Mar 20;14(3):e0213934. doi: 10.1371/journal.pone.0213934. eCollection 2019. |
| D009380 | Neoplasms, Nerve Tissue |
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |